This review article examines the efficacy and safety of the sustained-release combination of bupropion and naltrexone (Contrave) for treating mild-to-moderate obesity. Bupropion, a norepinephrine-dopamine reuptake inhibitor, and naltrexone, an opioid receptor antagonist, work synergistically to reduce appetite and cravings by modulating the hypothalamic melanocortin system and mesolimbic reward pathways. Clinical
